![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
The objective of this study was to determine the expression of transforming growth factor-beta1 messenger RNA (TGF-β1 mRNA) and the expression of mRNA for TGF-β receptors (TGF-β Rs mRNA) in whole peripheral blood of consecutive (treated from several months to several years) systemic lupus erythematosus (SLE) patients (21 women). A further aim of this study was to evaluate the association between expression of the above mentioned parameters in relation to the form of applied therapy (9 patients treated with quinagolide and 12 with quinagolide plus prednisone, azathioprine or cyclosporine A). The control group consisted of 15 healthy women. Most of the patients had mild SLE with SLE disease activity index (SLEDAI) score < 10 at time when blood samples were collected. Laboratory measurements included real-time polymerase chain reaction (RT-QPCR). The expression levels of TGF-β1 mRNA and mRNA for TGF-β RII and RIII were significantly lower in patients whereas the expression level of TGF-β RI was statistically significantly higher in SLE patients than in the controls. A very high positive correlation between TGF-β1 mRNA expression and expression levels of TGF-β Rs mRNA was found. In compared subgroups selected according to the form of the applied therapy no statistically significant differences were observed. We conclude that the TGF-β signaling pathway can be altered in circulating leukocytes derived from treated patients with SLE and that the assumed forms of the applied therapy in the group of patients under consideration are accompanied by similarity in the expression level of transcripts for TGF-β1 and TGF-β Rs determined in whole blood. In our investigations, we cannot exclude the influence of the disease itself on the obtained results.